Anbio Biotechnology (NASDAQ:NNNN) Short Interest Down 44.9% in August

Anbio Biotechnology (NASDAQ:NNNN) was the recipient of a large decline in short interest in August. As of August 14th, there was short interest totaling 26,210 shares, a decline of 44.9% from the July 30th total of 47,525 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 49,980 shares, the short-interest ratio is presently 0.5 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Anbio Biotechnology Stock Performance

NASDAQ NNNN traded down $0.11 on Friday, reaching $7.67. The stock had a trading volume of 252,350 shares, compared to its average volume of 159,615. The firm has a fifty day moving average of $10.51 and a two-hundred day moving average of $20.04. Anbio Biotechnology has a 1-year low of $6.61 and a 1-year high of $51.33.

Anbio Biotechnology Company Profile

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.